Advantages

A mid-sized, entrepreneurial firm with sales of €147 million in 2009, PharmaSwiss does what MNCs do only on a much smaller scale and in one specific region of the world.

Owned 58% by its two founders and 29% by the Swiss-based Healthcare private equity fund HBM Bioventures, 13% by Enterprise Investors (Polish Enterprise Fund VI), the oldest and largest country-based PE fund in CEE, PharmaSwiss is a professionally managed company. The management board is comprised of former multinational pharmaceutical executives with decades of management experience in this region, plus the CEOs of HBM Bioventures and Enterprise Investors. With these new investments, the firm is built on an even more solid foundation of financial security and integrity.

More information about HBM Bioventures is available at www.hbmbioventures.com

More information about Enterprise Investors is available at www.ei.com.pl

The backbone of the firm is a team of professionals who speak the languages of this region, know the markets and enjoy strong local partnerships. PharmaSwiss also offers the distinct advantages of:

• One delivery point
• One billing/payment point
• Bonded consignment stock in Ljubljana
• Direct deliveries 1 day from order
• Payments by wholesaler to PharmaSwiss
• Swiss-secured Euro payments to MNC partners
• GMP, GDP, GWP audited warehouses and distribution